A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma, Open-Angle; Ocular Hypertension
Intervention: 0.15% Brimonidine Tartrate (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Allergan Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan
Summary
This study will evaluate 0. 15% brimonidine tartrate in patients with primary open angle
glaucoma and ocular hypertension.
Clinical Details
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosis of open-angle glaucoma or ocular hypertension
Exclusion Criteria:
- Used Alphagan® in previous 3 months
Locations and Contacts
Shanghai, China
Additional Information
Starting date: July 2010
Last updated: June 24, 2014
|
